Strain Profile
Save
Bifidobacterium lactis DN-173 010
◔
Human-origin
Where this strain was first isolated, curated from the literature and culture-collection catalogs. It describes provenance only — not suitability, and not benefit.
How we classify this →
Sequenced
Whether a public genome assembly is linked for this strain. Without one the genome screens cannot run. It is not a verdict on the organism.
How we classify this →
Public genome assembly available
Bifidobacterium animalis subsp. lactis DN-173 010 (also marketed as Bifidus Regularis) is among the most studied probiotic strains in the context of digestive function, with multiple randomized controlled trials in humans. Human trials have examined gut transit time and abdominal distension, particularly in the context of functional constipation and irritable bowel syndrome; several studies have examined gastrointestinal survival and detectability of the strain in stool. The strain has been delivered primarily as fermented dairy products in research settings. Research on endpoints beyond digestive transit — including oral health and colon health — comes largely from early-stage or animal studies. These are research topics, not findings; the papers do not establish that this strain treats or prevents any condition.
Where it's been studied Tags come from a conservative keyword scan of each paper's title, abstract, and summary. A tag is research coverage, not measured effect. How we classify this →
Share of this strain's 50 body-system-tagged papers that concern each system. Research coverage, not measured effect.
Symptoms in the research A tag means the paper's text names the symptom or condition — research coverage, not evidence of benefit. How we classify this →
Share of this strain's 30 symptom-tagged papers that mention each symptom or condition. Research coverage, not evidence of benefit.
+5 more symptoms
Research Study-type filters use AI-classified labels, audited but not guaranteed — check the paper itself before leaning on one. How we classify this →
66 papers reference this strain in the probiotic database.
Match confidence
How strongly this paper was matched to this strain when the corpus was linked. It orders the list — it says nothing about the study's quality or its findings.
How we classify this →
2021
IN_VITRO
2016
META_ANALYSIS
2013
META_ANALYSIS
2010
ANIMAL
2009
RCT
2009
OBSERVATIONAL
2009
RCT
2009
RCT
2008
RCT
2008
RCT
2008
RCT
2008
REVIEW
2007
RCT
2007
RCT
2007
RCT
2007
ANIMAL
2005
ANIMAL
2005
REVIEW
2005
RCT
2005
ANIMAL
Browse all 66 papers →
Determination of Honey Varietals’ Impact on Bifidobacterium animalis ssp lactis Survivability in Commercial Yogurt Through Simulated In Vitro Digestion
· Current Developments in Nutrition
Contemporary meta-analysis of short-term probiotic consumption on gastrointestinal transit
· World Journal of Gastroenterology
Probiotic supplementation decreases intestinal transit time: Meta-analysis of randomized controlled trials
· World Journal of Gastroenterology
Bifidobacterium animalis subsp. lactis fermented milk product reduces inflammation by altering a niche for colitogenic microbes
· Proceedings of the National Academy of Sciences
Study on the Effect of Probiotic Yogurt Containing Bifidobacterium animalis DN-173 010 on Improving Constipation Symptoms
含动物双歧杆菌DN-173 010的益生菌酸乳对便秘症状改善作用的研究
· 胃肠病学
Fermented milk containing Bifidobacterium lactis DN‐173 010 improved self‐reported digestive comfort amongst a general population of adults. A randomized, open‐label, controlled, pilot study
· Journal of Digestive Diseases
Fermented milk containing Bifidobacterium lactis DN-173 010 improves gastrointestinal well-being and digestive symptoms in women reporting minor digestive symptoms: a randomised, double-blind, parallel, controlled study
· British Journal Of Nutrition
Clinical trial: the effects of a fermented milk product containing Bifidobacterium lactis DN-173-010 on abdominal distension and gastrointestinal transit in irritable bowel syndrome with constipation
· HAL (Le Centre pour la Communication Scientifique Directe)
Clinical trial: the effects of a fermented milk product containing Bifidobacterium lactis DN‐173 010 on abdominal distension and gastrointestinal transit in irritable bowel syndrome with constipation
· Alimentary Pharmacology & Therapeutics
Effect of the ingestion of a symbiotic yogurt on the bowel habits of women with functional constipation.
· PubMed
Effect of Bifidobacterium lactis DN-173 010 on the Intestinal Transit Time,the Condition of Defecation and Intestinal Microflora: A randomized, Double-blind,Placebo-controlled, Cross-over Study among Healthy Japanese Women.
· INRIA a CCSD electronic archive server
[The probiotic yogurt Activia shortens intestinal transit, but has not been shown to promote defecation].
· PubMed
Effect of a fermented milk containing Bifidobacterium animalis DN‐173 010 on the health‐related quality of life and symptoms in irritable bowel syndrome in adults in primary care: a multicentre, randomized, double‐blind, controlled trial
· Alimentary Pharmacology & Therapeutics
Survival of Bifidobacterium animalis DN-173 010 in the Faecal Microbiota after Administration in Lyophilised Form or in Fermented Product – A Randomised Study in Healthy Adults
· Microbial Physiology
Effect of a fermented milk containing Bifidobacterium animalis DN-173 010 on the health-related quality of life and symptoms in irritable bowel syndrome in adults in primary care: a multicentre, randomized, double-blind, controlled trial
· HAL (Le Centre pour la Communication Scientifique Directe)
BIFIDOBACTERIUM ANIMALIS DN-173 010 DOSE DEPENDENDLY PREVENTS STRESS-INDUCED INCREASE SENSITIVITY TO DISTENSION IN RATS
· HAL (Le Centre pour la Communication Scientifique Directe)
PASSCLAIM: consensus on criteria
· HAL (Le Centre pour la Communication Scientifique Directe)
Bifidobacteria as probiotic agents : physiological effects and clinical benefits
· HAL (Le Centre pour la Communication Scientifique Directe)
Effect of yogurt with Bifidobacterium DN-173 010 on salivary mutans streptococci and lactobacilli in young adults
· HAL (Le Centre pour la Communication Scientifique Directe)
Increasing ursodeoxycholic acid in the enterohepatic circulation of pigs through the administration of living bacteria
· British Journal Of Nutrition
Discussion
Be the first to comment.
Sign in to join the discussion.
No comments yet.
Citations
Selected papers that name this strain.
-
[1]
Source →Clinical trial: the effects of a fermented milk product containing Bifidobacterium lactis DN-173-010 on abdominal distension and gastrointestinal transit in irritable bowel syndrome with constipation· HAL (Le Centre pour la Communication Scientifique Directe) · 2009
-
[2]
Source →Effect of Bifidobacterium lactis DN-173 010 on the Intestinal Transit Time,the Condition of Defecation and Intestinal Microflora: A randomized, Double-blind,Placebo-controlled, Cross-over Study among Healthy Japanese Women.· INRIA a CCSD electronic archive server · 2008
-
[3]
PMID 18801055 →Clinical trial: the effects of a fermented milk product containing Bifidobacterium lactis DN‐173 010 on abdominal distension and gastrointestinal transit in irritable bowel syndrome with constipation· Alimentary Pharmacology & Therapeutics · 2008
-
[4]
Source →Effect of a fermented milk containing Bifidobacterium animalis DN-173 010 on the health-related quality of life and symptoms in irritable bowel syndrome in adults in primary care: a multicentre, randomized, double-blind, controlled trial· HAL (Le Centre pour la Communication Scientifique Directe) · 2007
-
[5]
Source →Recent Advances in the Use of Functional Foods: Effects of the Commercial Fermented Milk with Bifidobacterium Animalis Strain DN-173 010 and Yoghurt Strains on Gut Transit Time in the Elderly· Microbial Ecology in Health and Disease · 2003